- The folks at National Cancer Institute (NCI) are studying the effects of vismodegib; gamma-secretase/Notch signalling pathway inhibitor RO4929097; laboratory biomarker analysis; pharmacological study on Recurrent Uterine Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Kaposi Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Adult Malignant Fibrous Histiocytoma of Bone, Metastatic Osteosarcoma, Ovarian Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Adult Malignant Fibrous Histiocytoma of Bone, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Conjunctival Kaposi Sarcoma, Clear Cell Sarcoma of the Kidney, Chondrosarcoma, Adult Synovial Sarcoma, Adult Rhabdomyosarcoma, Adult Neurofibrosarcoma, Adult Malignant Mesenchymoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma, Adult Fibrosarcoma, Adult Extraskeletal Osteosarcoma, Recurrent Osteosarcoma, Adult Extraskeletal Chondrosarcoma, Adult Epithelioid Sarcoma, Adult Epithelioid Hemangioendothelioma, Adult Desmoplastic Small Round Cell Tumor, Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Small Intestine Leiomyosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma and Stage IV Uterine Sarcoma in individuals ages 18 years and older. This clinical trial is slated to start June 2010.
This study is officially titled, "A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas."
|Recruiting||Memorial Sloan-Kettering Cancer Center|
New York, New York, 10065
United States - map
|Mrinal M. Gounder||646-888-4226|
For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.